Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?

Estève Ribera, Luis Fernando López-Cortés, Vicente Soriano, José Luis Cañada and Josep Mallolas

Therapeutic drug monitoring is attracting growing interest as a means of increasing the effectiveness of antiretroviral therapy and of decreasing its toxicity, although data supporting this strategy are still scarce. Currently, nucleoside analog reverse-transcriptase inhibitors (NARTI) are not candidates because their effect depends on their active intracellular form and not on plasma concentration. Protease inhibitors (PI) and non-nucleoside analogue reverse-transcriptase inhibitors (NNARTI) meet the criteria for therapeutic drug monitoring. The main limitations are that the parameters to be monitored in order to measure exposure to the drug and the effective concentration of the drug have not been well defined. The few studies performed in treatment-naive patients have demonstrated that monitoring improves therapeutic efficiency. This strategy will be particularly useful when the risk of subtherapeutic or toxic concentrations is especially high (pharmacokinetic interactions, intestinal malabsorption, adverse effects, virological failure without obvious cause, pregnancy, children). Although it remains to be standardized, the inhibitory quotient integrates pharmacological and virological parameters and is useful in patients with prior virological failure. Any therapeutic drug monitoring program should be accompanied by measures to monitor and improve treatment adherence. There are good reasons to believe that therapeutic drug monitoring can be useful to improve treatment in specific circumstances. However, before its widespread use as a routine method can be recommended, the parameters to be used should be standardized and studies with appropriate methodology should be performed to define the role of therapeutic drug monitoring in distinct clinical situations.

Key words: Therapeutic drug monitoring. Pharmacokinetics. Protease inhibitors. Non-nucleoside analog reverse-transcriptase inhibitors. Inhibitory quotient.

Monitorización terapéutica y cociente inhibitorio de los fármacos antirretrovirales: ¿son aplicables a nuestra realidad?

La monitorización terapéutica es una estrategia terapéutica que suscita un creciente interés para mejorar la eficacia del tratamiento antirretroviral y disminuir su toxicidad, aunque los datos que la avalan son todavía escasos. Los inhibidores de la transcriptasa inversa análogos de nucleósidos (ITINN) no son actualmente candidatos, puesto que su efecto depende de la forma activa intracelular y no de la concentración plasmática. Los inhibidores de la proteasa (IP) y los de la transcriptasa inversa no análogos de nucleósidos (ITINN) satisfacen los criterios necesarios para ser candidatos a la monitorización terapéutica. Las principales limitaciones radican en que los parámetros a monitorizar para medir la exposición al fármaco y la concentración eficaz del mismo no se han definido adecuadamente. Los pocos estudios efectuados en pacientes no tratados previamente han demostrado que la monitorización mejora la eficacia terapéutica. La monitorización será particularmente útil cuando el riesgo de presentar concentraciones subterapéuticas o tóxicas es muy elevado (interacciones farmacocinéticas; malabsorción intestinal; efectos adversos, fracaso virológico sin una causa evidente, mujeres embarazadas, niños). El cociente inhibitorio integra parámetros farmacológicos y virológicos y es útil en los pacientes con fracasos virológicos previos, aunque es necesario su estandarización. Es importante que cualquier programa de monitorización terapéutica se acompañe de medidas para monitorizar y mejorar la adherencia al tratamiento. En definitiva, existe fundamento para pensar que la monitorización terapéutica puede ser una herramienta útil para optimizar el tratamiento en determinadas circunstancias; sin embargo, antes de recomendar su amplia aplicación como método de rutina es preciso estandarizar los parámetros que deben utilizarse y realizar estudios con una metodología adecuada para perfilar el papel de la monitorización terapéutica en diferentes situaciones clínicas.
Introduction
Highly active antiretroviral therapy (HAART) was a revolution in the management of HIV-infected patients, drastically reducing mortality and the incidence of opportunistic infections. In spite of the undeniable clinical benefits obtained, between 20% and 50% of patients who initiate HAART present virological failure during the first year of treatment and the incidence of failure increases rapidly during successive treatments. Treatment can fail for many reasons, which may be patient-, virus-, or drug-related. There can be no doubt as to the importance of obtaining a suitable virological response at the focus of virological multiplicity. If the concentration is greater than needed to inhibit the virus, viral replication will be suppressed and development of resistance mutations will be avoided. If the concentration is low, selective pressure on the virus will lead to the development of resistance to one or more drugs and virological failure. If, on the contrary, the concentration of the drug is very high, toxicity could increase. At present, pharmacological toxicity is the main reason for suspending treatment and an important contributor to poor adherence.

Monitoring the plasma concentration of some drugs has been in use for more than 30 years. The introduction of this scientific discipline in normal clinical practice has enabled us to reduce morbidity, mortality, adverse effects and hospital stay among some patients, although it can only be applied to a small group of drugs such as oral anticonvulants, digoxin, theophyllines, aminoglycosides, vancomycin, cyclosporine and other immunosuppressors. HIV therapy uses fixed doses of drugs and therapeutic drug monitoring does not form part of normal clinical practice, even though ART have certain characteristics which make them appropriate for therapeutic drug monitoring. The value of adjusting the antiretrovirals dose to maintain specific concentrations remains controversial. In recent years, therapeutic drug monitoring has aroused both interest and speculation concerning its role in the optimisation of ART.

The concept of therapeutic drug monitoring
This strategy allows the dose of a drug to be modified according to its plasma concentration, in order to maintain it within previously defined therapeutic limits, with the objective of improving therapeutic efficacy and/or avoiding toxicity.

Necessary requirements for drug monitoring to be potentially useful

Determination of the drug plasma concentration
Techniques that allow us to precisely determine the plasma or serum concentrations of all the currently available PIs and NNRTIs. Furthermore, we can simultaneously determine the concentration of several drugs in a single chromatography. Despite the fact that this technique has only been applied in a few large hospitals and reference centres, it can be carried out in any clinical laboratory with a chromatograph and qualified staff. At present, all laboratories can participate in an international quality control programme for the determination of PI and NNRTI concentrations. The cost of determining the concentration of a drug is considerably lower than that of other routine tests in HIV-infected patients. For example, determining the Cmax of a PI or an NNRTI in an external laboratory costs 20-30 €.

Determination of the NRTI plasma concentration is equally feasible. Nevertheless, it is necessary to know whether the drug need be phosphorylated inside the cells to exercise its action, the correlation between the blood levels of most compounds and their antiretroviral activities and/or potential toxicity is poor. Consequently, NRTIs are not currently recommended for therapeutic drug monitoring, although the interest in monitoring NRTI levels has shown us that tenofovir increases the plasma concentration of didanosine by 40-60%. This information has enabled us to recommend reducing the dose of didanosine in patients who receive concomitant tenofovir.

Wide interindividual variability of pharmacokinetic parameters
Therapeutic drug monitoring is only meaningful when the administration of the same dose to different patients can lead to variable concentrations. Were this not the case, the concentration of the drug would be very predictable, and knowing the dose would almost be the same as knowing the plasma concentration.

At present, patients treated with PIs or NNRTIs receive the same dose, and one of the most common problems is the huge interpatient variability of the plasma concentrations. The AUC, Cmax or Cmin frequently vary more than 10-fold between different patients receiving the same dose. This wide interpatient variability is basically due to differences in the activity of the isoenzymes of the cytochrome P450 system and the transporter proteins or efflux pumps (glycoprotein P, etc.) responsible for the absorption and metabolism of PIs and NNRTIs. Other factors, such as weight, age, presence of chronic liver disease and drug-drug interactions can also play an important role.

Even when small doses of ritonavir are administered to inhibit cytochrome P450 and the efflux pumps, interpatient variability is still very wide.

Searce intrapatient variability of pharmacokinetic parameters
For therapeutic drug monitoring to be viable, it is important that a single determination of the plasma concentration has a considerable value. If there was a wide intrapatient variability, monitoring would be practically impossible, as determining the plasma concentration of a drug today would not provide us with information on the plasma concentration tomorrow, next week or next month.

Few studies have evaluated the intrapatient variability of ART, but those that do have observed that the concentration of PIs and NNRTIs in the same patient is relative-
ly constant, with variation coefficients of 30-45%. Therefore, a single determination of these drugs would give us reliable information on the concentrations maintained by the patient. Obviously, pharmacokinetic stability will break down if patient circumstances change, especially if adherence is poor, but also if absorption is altered (due to diarrhoea, for example, or intestinal malabsorption) or if the patient takes other drugs or non-pharmacological products which interact with antiretrovirals.

Good correlation between plasma concentration and therapeutic efficacy or toxicity

If the correlation between plasma concentration and clinical response was not good, therapeutic drug monitoring would be of no use. This seems to be the case with NRTIs. No clear relationship has been established between the plasma concentration of NRTIs and response to therapy. NRTIs are prodrugs which are activated inside the cell by kinase action and become active triphosphate derivatives. These reactions limit the amount of intracellular active drug. Determination of the intracellular concentration of NRTI-triphosphate could be more useful for predicting the response to therapy, but this requires very complex techniques. Mass spectrometry is used, although it is only available in some research laboratories.

Unlike NRTIs, PIs and NNRTIs do not require intracellular metabolism to be active. Several studies show the relationship between PI plasma concentration and response to therapy, especially in ART-naive patients. A relationship has also been observed between high concentrations of ritonavir, indinavir, nelfinavir and amprenavir, and a greater incidence of adverse reactions. Some types of digestive toxicity from PIs are caused by local action on mucosa and it is no surprise that the plasma concentration of nelfinavir is not associated with diarrhoea.

As far as NNRTIs are concerned, both efavirenz and nevirapine have a longer elimination half-life than PIs. This is seen through smaller oscillations in plasma concentrations are as marked as with PIs. High concentrations of efavirenz have been associated with liver toxicity and rash. If we take into account the significant correlation between pharmacokinetic parameters such as AUC, Cmax, and/or Cmin, and the response to ART or toxicity, it seems logical to suppose that maintaining plasma concentrations within certain levels will optimise its use.

Narrow therapeutic margin

 Drugs with a wide therapeutic margin can be administered relatively easily at a fixed dose, and effective, non-toxic concentrations can be reached. Therapeutic drug monitoring will be more useful when the difference between the effective concentration and the toxic concentration is small. Most PIs have a relatively small therapeutic margin and the mean Cmin of patients receiving non-boosted PIs is slightly above the effective concentrations. Around 30-40% of patients have been estimated to present PI concentrations lower than those which are considered effective. The administration of small doses of ritonavir enormously increases the plasma concentrations of PIs and, at present, all PIs, with the exception of nelfinavir, are usually combined with ritonavir. It is extremely unusual for the concentration of saquinavir, indinavir, amprenavir or lopinavir boosted with ritonavir to be sub-therapeutic in patients who do not present resistance to PIs, except in cases of poor adherence. Nevertheless, therapeutic drug monitoring of PIs boosted with ritonavir is still useful, given that wide interpatient variability is maintained and that, by increasing the concentration of the PI, the number of adverse effects can rise. In addition, even if the concentration is therapeutic for non-resistant viruses, it may be insufficient for viruses with several mutations.

Characteristics which make the monitoring of antiretrovirals difficult

Confusion between adherence to therapy and plasma concentration

Adherence to ART is essential if therapy is to be suitably efficacious and durable, although it is difficult to maintain good adherence to all drugs, if we take into account doses, dosing intervals and dietary requirements. For therapeutic drug monitoring to be clinically useful, a knowledge of adherence is necessary and adherence must be good. A suitable plasma concentration does not necessarily mean that adherence will be good, as the patient may be more attentive to taking medication before the monitoring visit. A low plasma concentration may reflect a pharmacokinetic problem, poor adherence, or both. It is, therefore, important to evaluate and optimise adherence and, if possible, determine the drug plasma concentration after ingestion. If the concentration is low, we should insist on the importance of adherence, as measuring adherence can be difficult in some patients. In this context, sub-therapeutic concentrations can help us to discover cases of poor adherence. The plasma concentration is more variable in patients with poor adherence, and sub-therapeutic concentrations of PIs or NNRTIs have been used as another parameter to be taken into account when evaluating adherence. Therapeutic drug monitoring is of little use to know the adherence of drugs with a short half-life, but it may be more useful in the case of drugs with a longer half-life, such as NNRTIs or some boosted PIs (e.g. lopinavir/ritonavir). If adherence is correct, we should rule out other causes, such as pharmacokinetic actions or intestinal malabsorption, which can lead to sub-therapeutic concentrations.
TABLE 1. Dose, therapeutic target concentrations for wild-type viral isolates and minimum concentrations of protease inhibitors and non-nucleoside reverse transcriptase inhibitors

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose (mg)</th>
<th>IC_{50}/IC_{90}/IC_{95} (µg/mL)</th>
<th>Effective concentration (µg/mL)²</th>
<th>Mean values of C_{min} (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amprenavir</td>
<td>1,200 b.i.d.</td>
<td>0.006-0.015</td>
<td>0.25</td>
<td>0.28-0.45</td>
</tr>
<tr>
<td>Amprenavir/ritonavir</td>
<td>600/100 b.i.d.</td>
<td>1.10-1.40</td>
<td>1.77</td>
<td></td>
</tr>
<tr>
<td>Saquinavir</td>
<td>2,000 t.i.d.</td>
<td>0.002-0.041</td>
<td>NA</td>
<td>0.16-0.22</td>
</tr>
<tr>
<td>Saquinavir/ritonavir</td>
<td>300/100 q.d.</td>
<td>1.02-1.41</td>
<td>2.12</td>
<td></td>
</tr>
<tr>
<td>Indinavir</td>
<td>800 t.i.d.</td>
<td>0.015-0.061</td>
<td>0.10</td>
<td>0.15-0.21</td>
</tr>
<tr>
<td>Indinavir/ritonavir</td>
<td>300/100 b.i.d.</td>
<td>0.03-0.11</td>
<td>0.50</td>
<td>0.70-0.95</td>
</tr>
<tr>
<td>Lopinavir/ritonavir</td>
<td>1,200 q.d.</td>
<td>0.003-0.054</td>
<td>0.05</td>
<td>0.07-0.16</td>
</tr>
<tr>
<td>Suquinavir</td>
<td>1,000/100 b.i.d.</td>
<td>0.008-0.036</td>
<td>1.4-3.4</td>
<td>2.25-3.73</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>600 b.i.d.</td>
<td>0.00014-0.0021</td>
<td>1.00</td>
<td>1.77</td>
</tr>
</tbody>
</table>

For viruses with no reduction in susceptibility:

- IC_{50}/IC_{90}/IC_{95}: inhibitory concentration 50%/90%/95%; b.i.d.: two per day; q.d.: every day; t.i.d.: three per day; NA: not available.

*Difficulties in establishing an efficacious concentration*

Despite abundant literature showing the relationship between the concentration of a drug and response to therapy, the therapeutic range of PIs and NNRTIs in different situations is not clearly defined. Table 1 shows the proposed therapeutic concentrations in some studies, although we should not forget that these data have not yet been sufficiently validated in clinical practice.

The first doubt concerns which of the pharmacokinetic parameters (AUC, C_{max} or C_{min}) best predicts the clinical efficacy of PIs or NNRTIs. These parameters are closely related, even though they provide us with different pharmacokinetic data.

The AUC tells us about the total exposure to the drug and has been related to efficacy and toxicity. The AUC, C_{max} or C_{min} are necessary throughout the dosing interval (8, 12 or 24 hours), with the result that a large number of blood samples are necessary throughout the dosing interval, or trough, concentration (C_{trough}), 90% (IC_{90}), or 95% (IC_{95}) of viral replication. This inhibitory concentration is corrected by the drug’s binding to plasma proteins to obtain a parameter which would theoretically correspond to the EC \( EC_{50}=EC_{90}=EC_{95} \). This correction by binding to proteins can occur in several ways, with very different results.

Since viral replication must be inhibited as much as possible, the EC_{50} or the EC_{95} would be more suitable than the EC_{90}, although the EC_{95} is generally used as it can be determined more precisely.

The C_{max} is the most widely studied pharmacokinetic parameter in the literature, and that which is most associated with virological efficacy, although also with virological efficacy. In a recent study, the C_{max} of indinavir was the only parameter associated with an increase in the number of CD4 lymphocytes in patients with HIV replication to be inhibited permanently, effective concentrations (EC) of the drug during the therapeutic interval are necessary, so that, if the C_{min} is greater than the EC, the virus would be inhibited correctly. This alleged EC is a theoretical concentration which can be found in the literature and which has been calculated in vitro from a phenotypic study of strains susceptible to the virus. In this way, we can determine the concentration of the drug necessary to inhibit 50% (IC_{50}), 90% (IC_{90}), or 95% (IC_{95}) of viral replication.

50% Drug Dose (mg) IC_{50}/IC_{90}/IC_{95} (µg/mL) Effective concentration (µg/mL)² Mean values of C_{min} (µg/mL)

For viruses with no reduction in susceptibility:

- IC_{50}/IC_{90}/IC_{95}: inhibitory concentration 50%/90%/95%; b.i.d.: two per day; q.d.: every day; t.i.d.: three per day; NA: not available.

*Refers to the literature and which has been calculated from the pre-dose, or trough, concentration (C_{trough}), which is usually determined, and the minimum concentration (C_{min}), which is the lowest concentration. These terms are often confused, and the literature generally refers to C_{min} when it means C_{trough}. For most drugs, both concentrations are very similar, as the concentration begins to increase shortly after administration, and the terminal half-life is not clinically relevant. For other drugs, such as lopinavir or ritonavir, the difference can be considerable, since the concentration continues to fall for one or two hours.*
of lopinavir are much higher than that which is necessary to inhibit sensitive viruses, but when the virus has accumulated a certain number of resistance mutations to PIs, this difference could be important. A second disadvantage of C\textsuperscript{min}, is the circadian rhythm of some PIs, such as nelfinavir or saquinavir, with concentrations which are considerably lower at night than in the morning\textsuperscript{23}. In these cases, the lowest concentration during the dosing interval would be the night-time C\textsuperscript{min}. A third problem is that C\textsuperscript{min}, unlike C\textsuperscript{max} and AUC, is usually determined without directly observing the administration of the previous dose of the drug. It is therefore difficult to take blood samples at the expected time (8, 12 or 24 hours after intake, depending on the dosing interval), because the patient has taken the drug early/late, or because he/she arrived late for the visit or because of the workload of the person taking the sample. With PIs, a poor choice of extraction time can provide a sample which is not representative of what we wish to evaluate. NNRTIs, in particular efavirenz, have a prolonged half-life, so that lack of precision with sampling time has less effect on the results. In the study by Marzolini et al\textsuperscript{97}, where the concentration of efavirenz was associated with therapeutic efficacy and toxicity, samples were taken indiscriminately between eight and twenty hours after administration.

Data from the literature have enabled us to generate concentration-time curves which include the percentiles 10, 25, 50, 75 and 90 of the simulated concentrations of the main therapeutic regimens with boosted and non-boosted PIs and with NNRTIs\textsuperscript{98}. These curves allow us to extrapolate, with acceptable precision, the result of a sample obtained at any time interval to the population parameters. This method requires an accurate knowledge of the time of administration and the time of sampling. For drugs with a short half-life, as is the case with most PIs, errors of just a few hours can render the result inaccurate. For drugs with a prolonged half-life, such as the NNRTIs, this error is of little importance.

An additional problem when determining whether the concentration lies within therapeutic margins is that we must realize that what we are determining is the total concentration of the drug and not the free fraction, i.e. the part which spreads to the tissues and inhibits the virus. Both for PIs and for NNRTIs, the greater part of the drug in plasma is bound to plasma proteins, mainly to acid alpha1-glycoprotein and albumen. Alpha 1-glycoprotein is an acute phase reactant and its concentrations can vary considerably under certain circumstances\textsuperscript{99}, for example, in the case of intercurrent infections. Therefore, it may be important to determine the concentration of a drug in a stable clinical situation. There is noticeable interpatient and intrapatient variability in the protein-bound fraction of indinavir\textsuperscript{100}, and changes have been observed in the proportion of free lopinavir during the therapeutic interval\textsuperscript{101}, although the clinical significance of this is unknown.

The presence of active metabolites which contribute to the overall efficacy of drugs can also make it difficult to interpret the plasma concentration. Nelfinavir is the only drug among those studied to therapeutic drug monitoring for which an active metabolite (M8) is known, with measurable concentrations in plasma. M8 is as active as nelfinavir itself and is less bound to plasma proteins. The precise role it plays in the overall activity of nelfinavir is unknown.

Co-administration of ritonavir and nelfinavir slightly increases the concentration of nelfinavir but greatly increases the M8/nelfinavir quotient.

Finally, we must not forget that the necessary concentration of the medication must be interpreted on an individual basis. Expectations which arise from patients infected by viruses with mutations which reduce susceptibility to PIs, may require higher concentrations of PIs (see section "Inhibitor status") or that we substantially increase if the quotient is below 0.9, whereas for indinavir, it was increased or reduced if the quotient was not within the range 0.75-2. After one year of follow-up, the number of patients with a viral load < 50 copies/mL by intention-to-treat (loss = failure) was significantly greater in the monitoring group than in the control group (78.2% vs. 60.5%).
A trough concentration greater than the IC

type of the virus and were randomized to compare fol-\

cations may obtain a considerable benefit.

presenting sub-inhibitory or extremely high concentra-

ing, it is clear that it cannot be applied easily to all pa-

eficacy of ART by 5%. Given these limitations, the cost

may not be very important. Unless it is also used as an-

can be applied to the current situation?

In the first place, monitoring is recommended when

there are likely to be pharmacokinetic interactions. The amount of possible interactions in HIV-infected patients

receiving ART is enormous\textsuperscript{123-125}, depending mainly on the

inhibition or induction of the enzyme systems responsible for the absorption or metabolism of the medication (cy-

tochrome P 450, transporter proteins). In general, PIs are

enzyme inhibitors and NNRTIs are enzyme inducers. Many other drugs may be important enzyme inducers (e.g.

rifampicin, rifabutin) or inhibitors (e.g. azoles). In tuber-

culosis, which is often associated with HIV infection, ther-

apeutic drug monitoring can be recouped for some

drugs, due to the drug-drug interactions which the disease

leads to\textsuperscript{105,106}. Even the so-called "natural medicine" can

cause interactions with ART\textsuperscript{123}. Sometimes the combi-

nation of inhibitors and/or inducers can give rise to very complex

and unpredictable interactions, as has recently been ob-

served with the combination of lopinavir/ritonavir and

amprenavir, which lead to marked drops in the concentra-

tions both of lopinavir and amprenavir\textsuperscript{125-127}. Therefore,

therapeutic drug monitoring is essential in these cases. These are many guidelines for dosing drugs with known

interactions, but we must not forget that the recommenda-

dions are generally based on mean concentrations. The

wide interpatient variability means that, in many cases,

the concentrations obtained are sub-therapeutic or ex-

tremely high. In the case of interactions, if possible, it

would be advisable to know the concentration of antiretro-

viral before and after adding the new drug in order to

evaluate the magnitude of the interaction and modify the

dose accordingly.

Another situation where therapeutic drug monitoring

could prove useful is the appearance of adverse effects. It

is sometimes difficult to know which drug is responsible

for a particular toxicity, but many adverse effects are

clearly associated with specific drugs and a dose reduction

could revert, for example, the renal toxicity of indinavir

or the toxicity of other PIs\textsuperscript{122}.

Therapeutic drug monitoring could also be useful in

once-daily regimens with drugs which do not have a long

half-life, such as PIs boosted with ritonavir. The C\textsubscript{min}

of most PIs boosted with ritonavir and of nevirapine is low-

er if the same dose of the one-daily drug is spread over

two intakes\textsuperscript{128,129,130,131}. It is important to know the C\textsubscript{min}

to avoid exposure to sub-inhibitory concentrations, especial-

ly when there already exists a certain degree of resistance
to the drug.

Therapeutic drug monitoring is particularly important in

the case of virological failure, which may be associated

with a sub-therapeutic concentration of the drug. In some

cases, increasing the concentration (e.g. PI boosted with

ritonavir) could make the drug efficacious again\textsuperscript{132,133}. The

therapeutic efficacy of successive regimens after virologi-

cal failure is increasingly low. In patients with few ther-

apeutic options, ART must be maximized to give an accept-

able response, and correct pharmacological concentrations

will enable us to increase virological efficacy and reduce

toxicity (see Section "Inhibitory quotient").

In patients with chronic liver disease, there have been

reports of greater variability\textsuperscript{134} or higher concentrations

of some drugs\textsuperscript{120,121}, which can increase toxicity\textsuperscript{135}. In this

sense, therapeutic drug monitoring may be especially use-

ful in cases of advanced liver disease to attempt to reduce

Selection of patients for whom therapeutic
drug monitoring can be particularly useful

Current efficacy of ART is high, and as many as 80-85%

of patients with good adherence have an undetectable vi-

ral load after one year of treatment. With these figures,

the contribution of universal therapeutic drug monitoring

may not be very important. Unless it is also used as an-

other measure of adherence, at most it could improve the

efficacy of ART by 5%. Given these limitations, the cost

can be an important problem when monitoring therapeutic drug monitor-

ing, it is clear that it cannot be applied easily to all pa-

tients. On the other hand, patients with a special risk of

preventing sub-inhibitory or extremely high concentra-

tions may obtain a considerable benefit.
toxicity in patients who are already prone to complications.

Some covariables, such as weight, sex or race can modify the pharmacokinetics of antiretrovirals. Overall, the correlation between concentration and weight is not very good in adults and neither PIs nor NNRTIs are adjusted to weight, although in overweight patients there may be a noticeable influence. In extremely overweight patients, it may be useful to determine the concentration in order to correct sub-therapeutic concentrations, and in very underweight patients, monitoring may help avoid toxicity. There have been reports in women of high of some drugs such as saquinavir, regardless of weight or body mass. This greater concentration in women has been associated with the greater efficacy, but also with greater toxicity, and so that if toxicity appears, it may be useful to determine the concentration and reduce the dose if it is high. The risk of presenting adverse reactions to nevirapine (skin rash and liver toxicity) is considerably higher in women than in men. Special mention must be made of the racial differences related to polymorphisms at codon 516, which may be responsible for higher levels of efavirenz-induced toxicity. Thus finding guarantees the possibility of pharmacogenomic studies alongside pharmacokinetic studies to optimise treatment.

Pregnant women are a population in which therapeutic drug monitoring is important. It has been shown that pregnancy can modify the pharmacokinetics of some drugs, especially during the third term, with wide variability in plasma concentrations. The concentrations of non-boosted indinavir and saquinavir sometimes fall to sub-therapeutic values, whereas that of nelfinavir is hard to modify. If we determine the Cmin during the first term, we can have a reference of the baseline concentration. If it falls during the second or third term, the dose can be adjusted to avoid sub-therapeutic concentrations.

Therapeutic drug monitoring can be particularly useful in children. Despite the fact that we have more results from pharmacokinetic studies on children, many antiretrovirals have not been studied in neonates or small children. The pharmacokinetics of many drugs in children is different to that observed in adults, and it can change over time as the body matures. In children, many antiretrovirals are administered in mg/kg or mg/m², but this does not guarantee adequate concentrations and therapeutic drug monitoring may be recommended to administer a dose which would provide adequate concentrations. In a review of clinical studies which analyse ART in children, 4 of the 23 studies adjusted the dose according to pharmacokinetic parameters. In these studies, the therapeutic efficacy was greater than that of other studies which used fixed doses. In children, therapeutic drug monitoring has also proved useful to ascertain adherence.

**Inhibitory quotient**

When we use the Cmin referring to the theoretical ECmin of each virus, we have been reports in women of high of some drugs, but it is often not the case in patients who have presented one or more virological failures. Despite the methodological doubts they present, therapeutic drug monitoring studies which have used these parameters in patients with previous virological failure have not shown the strategy to be useful. In patients who receive PIs, virological failures usually involve the emergence of mutations which reduce viral susceptibility to PIs, so that the drug concentration which is effective against sensitive viruses is not effective against viruses with reduced susceptibility. To solve this problem, the concept of inhibitory quotient (IQ) has appeared. The IQ is a parameter which relates the concentration of the drug to the susceptibility of the virus. It is a quotient whose numerator corresponds to exposure to the drug and whose denominator corresponds to the resistance to the virus. Thus, the greater the concentration of the drug and the lower the resistance to the virus, the greater will be the IQ, whereas the lower the concentration and the greater the resistance, the lower will be the IQ. As a measure of exposure to the drug, any one of the pharmacokinetic parameters (AUC, Cmax or Cmin) can be used, although Cmin has traditionally been the most common. As a measure of resistance, the EC50 of the sensitive virus referred to in the literature.

One of the main problems of using the IQ as a reference parameter for therapeutic drug monitoring is the need to phenotype the virus. The technique is very complex, expensive and can only be carried out in a few laboratories worldwide. Therefore, its application in clinical practice is impossible. To solve this problem, the so-called virtual inhibitory quotient (vIQ) has been developed, which, instead of using the real phenotype, uses the virtual phenotype. The virtual phenotype is an interpretation of the genotype which can be made thanks to a database with many genotypes and with the real phenotype corresponding to this genotype. Thus, in order to know the virtual phenotype, we need only know the genotype of the virus and apply a computer program which will allow us to interpret it. The result is the number of times the susceptibility of the virus is reduced. To calculate the denominator of the vIQ, we must multiply the value of the virtual phenotype by the EC50 of the sensitive virus referred to in the literature.

The IQ, corrected by the binding of the drug to plasma proteins intervenes in both the IQ and the vIQ. As mentioned above, this corrected IQ, is not standardised and can be calculated in different ways with very different results. In order to avoid this problem, the normalized inhibitory quotient (nIQ) has been developed. The numerator is the vIQ and the denominator is the reference vIQ corresponding to the vIQ which, in the studies carried out to date, has proven useful in predicting the efficacy of the drug. The same corrected IC50 intervenes in both the numerator and denominator and can therefore be eliminated. Thus, the numerator is left with the product of the Cmin by the phenotype (number of times susceptibility is reduced) and the denominator with a different reference value for each drug, which corresponds to the product of the...
TABLE 2. Types of inhibitory quotient (IQ) and their correlation with efficacy (virological response)

<table>
<thead>
<tr>
<th>IQ</th>
<th>Cmin/IC50</th>
<th>phenotype, corrected by binding to protein</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Logarithmic values of IC50 for lopinavir &lt; 4, 4 to 15, and &gt; 15 were associated with virological response at 24 weeks in 70, 80 and 100% of 57 patients in a rescue regimen with efavirenz + ritonavir/lovipavir. The IQ of efavirenz and the phenotypic result with lopinavir were also predictors of efficacy at 24 weeks.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The IQ was the best predictor of early virological response in 27 patients receiving ritonavir/lovipavir + amprenavir. An IQ &gt; 0.8 compared with amprenavir was the best predictor of virological efficacy at 24 weeks in 22 patients receiving rescue therapy with ritonavir + amprenavir.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>In 27 heavily PI-experienced patients, the virological response to nefavir and indinavir was greater in the case of an IQ &gt; 1.12 vs 0.80 log.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Significant correlation between IQ with nefavir boosted with saquinavir or ritonavir and fall in viral load at 12 weeks in 52 patients receiving rescue therapy (r = −0.39).</td>
<td></td>
</tr>
<tr>
<td>Virtual IQ (vIQ)</td>
<td>Cmin/IC50</td>
<td>phenotype, corrected by protein binding</td>
</tr>
<tr>
<td></td>
<td>Virological response (undetectable viral load or fall of 0.5 log) in 69% of patients receiving rescue therapy with r/lopinavir (600/400) and who present a vIQ &gt; 2, compared with 11% of those with a vIQ &lt; 2. vIQ was the best predictor at 12, 24 and 48 weeks.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>In the rescue combination with r/lovipavir + amprenavir, a vIQ &gt; 15 for lopinavir and &gt; 1.5 for amprenavir was associated with undetectable viral load in 86% of patients. Responders presented a median vIQ for lopinavir of 12.3 (in comparison with 1.92 in the non-responders).</td>
<td></td>
</tr>
<tr>
<td>Normalized IQ (nIQ)</td>
<td>Cmin/IC50</td>
<td>phenotype (virtual or real) of the drug/population Cmin, reference (cut-off CI50/phenotype (virtual or real))</td>
</tr>
<tr>
<td></td>
<td>In 52 rescue patients with r/lopinavir, a vIQ &gt; 14.5 was associated with a fall in viral load of approximately 2.7 log, whereas vIQ values under 0.6 led to falls of approximately 0.6 log.</td>
<td></td>
</tr>
<tr>
<td>Genotypic IQ (gIQ)</td>
<td>Cmin/number of mutations in the genotypic analysis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Significant correlation between gIQ and fall in viral load at week 12 (r = 0.49), in rescue therapy with 49 patients combining ritonavir and amprenavir. More efficacious parameter than drug levels and number of mutations separately.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Correlation between gIQ and virological response, with 78% of patients with gIQ &gt; 0.7 reaching a virological response in rescue therapy with lopinavir, in comparison with only 42% with gIQ below this figure. In the multivariate analysis, it was a better predictor than drug levels or number of mutations.</td>
<td></td>
</tr>
</tbody>
</table>

Population Cmin and the phenotype below which the drug conserves its clinical efficacy. This reference value has been only established for a few drugs. Another inhibitory quotient has recently been defined, which uses the genotype as a measure of viral resistance, thus avoiding the need to have the real or virtual phenotype. This quotient is known as the genotypic inhibitory quotient gIQ, which is defined as the quotient of the Cmin, and the number of mutations which reduce the susceptibility of the drug. Studies to date have observed that either of the inhibitory quotients makes much better than the isolated Cmin to the therapeutic response to different PIs in patients with previous virological failure and reduced viral susceptibility. Undoubtedly, the inhibitory quotient will be very useful in this setting, although the wide variety of ways to calculate the inhibitory quotient and the requirements of some of them make it necessary to agree on a standard before applying it to normal clinical practice.

Table 2 shows the different types of inhibitory quotient and their correlation with response to therapy.

Final comments and conclusions

1. Individual dosing according to plasma concentration is a therapeutic strategy has aroused interest in improving the efficacy of ART and in reducing its toxicity.
2. The immediate objective of therapeutic drug monitoring is the detection and correction of pharmacokinetic problems. Therapy does not only involve increasing or decreasing the dose of a drug, but it must also affect the underlying pharmacokinetic problem in each case (e.g. changing another drug which interacts with antiretrovirals, patient education on specific problems, etc.). We must not forget that therapeutic drug monitoring is not a strategy for treating the drug concentration but for treating the patient. For example, if the drug concentration is very high but the patient does not present toxicity, it would be difficult to find reasons to reduce the dose. Sometimes, therapeutic drug monitoring has been used as a complementary parameter to determine adherence to treatment.
3. The criteria a drug must fulfill to be suitable for therapeutic drug monitoring are:
   a) Possibility of determining the drug concentration using accurate laboratory methods which are available in normal clinical practice.
   b) Good relationship between plasma concentration, therapeutic efficacy and the appearance of adverse effects, in such a way that maintaining this concentration within specific margins can be beneficial.
   c) Narrow therapeutic margin, with a relative facility for presenting sub-therapeutic or toxic concentration.
   d) Wide interpatient variability and scarce intrapatient variability of the drug concentrations.
4. PIs and NNRTIs fulfill the suitability criteria for therapeutic drug monitoring. NRTIs do not and cannot currently be considered suitable for therapeutic drug monitoring.
5. Limitations to therapeutic drug monitoring include:
   a) Confusion between pharmacokinetic problems which lead to a low drug concentration and poor adherence.
   b) Inadequately defined parameters for measuring exposure to the drug and its efficacious concentration. Different pharmacokinetic parameters have been used to measure exposure to the drug, and a single sample, usually Cmax, is recommended in clinical practice. It may be difficult to know exactly when to take the sample with respect to taking the medicine (this is more important for PIs than for NNRTIs). The concentration determined must be a concentration which is considered therapeutic. This can be
obtained by mathematical calculations using theoretical concentration-time curves, but the IQc, corrected by binding to plasma proteins, which is found in the literature, is usually taken as a reference. This correction can be made in different ways, with different results. Moreover, the free fraction of the drug can vary in certain circumstances. In the case of nelfinavir, the presence of an active metabolite in considerable quantities can make it difficult to interpret the results. One of the most important problems is the choice of efficacious reference concentrations, which may not be useful for partially resistant viruses.

6. Very few randomized clinical trials have been carried out to evaluate the use of therapeutic drug monitoring, although those involving naive patients have shown that therapeutic drug monitoring improves the efficacy of treatment. The studies carried out in patients with therapeutic failure have not observed differences in efficacy, although they are affected by important problems of approach and methodology which make it impossible to interpret the results. One of the most important problems is the choice of efficacious reference concentrations, which may not be useful for partially resistant viruses.

7. The concept of inhibitory quotient includes both pharmacokinetic data and viral resistance data. In this way we can evaluate whether the plasma concentration of the drug is the appropriate concentration for a virus with a specific susceptibility. The inhibitory quotient is related to the efficacy of treatment in patients with virus who present reduced susceptibility and may be useful for therapeutic drug monitoring. Nevertheless, methodological standardization and a clinical validation are necessary before applying it in normal clinical practice.

8. Therapeutic drug monitoring will be particularly useful when the risk of sub-therapeutic or toxic concentrations is very high. Therefore, it is recommended in patients with any of the following characteristics:

a) Suspected clinically important pharmacokinetic interactions.

b) Suspected intestinal malabsorption.

c) Appearance of adverse effects which can improve with a reduced plasma concentration of the drug, especially in low-weight patients, women and in patients with cirrhosis of the liver.

d) Virological failure with no evident cause.

e) Pregnant women and children, whose pharmacokinetics can suffer modifications.

f) Patients who start ART with drugs which have relatively low concentrations, such as non-boosted PIs or one-daily treatments with some boosted PIs.

9. Boosting of PIs with ritonavir considerably increases their plasma concentration, although this does not invalidate their usefulness in therapeutic drug monitoring, given that a high pharmacokinetic variability may persist and viruses with reduced susceptibility may need higher concentrations of PI.

10. It is important that any therapeutic drug monitoring program contain measures to monitor and improve adherence, thus making it easier to interpret concentrations and provide a suitable response to therapy.

11. In summary, there is a clear basis for thinking that therapeutic drug monitoring may be a useful tool for optimizing ART in certain circumstances. Before recommending its widespread application as a routine method in normal clinical practice, it is necessary to standardise the parameters which must be used and carry out methodologically correct studies with a high number of patients to profile the role of therapeutic drug monitoring in different clinical situations. It may also be necessary to develop education programs for physicians, pharmacists, health-care personnel and patients, so that the information obtained from monitoring can be used properly.

Acknowledgements
We are grateful to Dr. Rosa Mª López Galera for her collaboration in the preparation of this manuscript.

References
Ribera E, et al. Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?


154. Kempf D, Hsu A, Jiang P, Rade S, Hertogs K, Roder B. Response to ritonavir intensification in lopinavir recipients is highly correlated with virtual inhibitory quotient. 8th Conference on Retroviruses and Opportunistic Infections; Chicago, 2001 [abstract 523].


156. Fletcher CV, Cheng H, Fauze SA, Stearns E, Habbich R. The inhibitory quotient (IQ) for saquinavir predicts virologic response to salvage therapy. 9th Conference on Retroviruses and Opportunistic Infections; Seattle, 2002 [abstract 129].


165. Platts PJ. The utility of inhibitory quotients in determining the relative potency of protease inhibitors. AIDS. 2002;16:799-800.